Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1987 Mar;84(6):1487–1491. doi: 10.1073/pnas.84.6.1487

Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model.

N V Katre, M J Knauf, W J Laird
PMCID: PMC304459  PMID: 3494243

Abstract

Recombinant human interleukin 2 purified from Escherichia coli has limited solubility at neutral pH and a short circulatory half-life. This recombinant interleukin 2 was chemically modified by an active ester of polyethylene glycol. The modified interleukin 2 was purified by hydrophobic interaction chromatography and characterized by sodium dodecyl sulfate/polyacrylamide gel electrophoresis and isoelectric focusing. This conjugate was compared to unmodified recombinant interleukin 2 in vitro and in vivo. Covalent attachment of the hydrophilic polymer polyethylene glycol enhanced the solubility of interleukin 2, decreased its plasma clearance, and increased its antitumor potency in the Meth A murine sarcoma model.

Full text

PDF
1487

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abuchowski A., Kazo G. M., Verhoest C. R., Jr, Van Es T., Kafkewitz D., Nucci M. L., Viau A. T., Davis F. F. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys. 1984 Jun;7(2):175–186. [PubMed] [Google Scholar]
  2. Beauchamp C. O., Gonias S. L., Menapace D. P., Pizzo S. V. A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. Anal Biochem. 1983 May;131(1):25–33. doi: 10.1016/0003-2697(83)90131-8. [DOI] [PubMed] [Google Scholar]
  3. Carlsson J., Drevin H., Axén R. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem J. 1978 Sep 1;173(3):723–737. doi: 10.1042/bj1730723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666–3670. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Devos R., Plaetinck G., Cheroutre H., Simons G., Degrave W., Tavernier J., Remaut E., Fiers W. Molecular cloning of human interleukin 2 cDNA and its expression in E. coli. Nucleic Acids Res. 1983 Jul 11;11(13):4307–4323. doi: 10.1093/nar/11.13.4307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Donohue J. H., Lotze M. T., Robb R. J., Rosenstein M., Braziel R. M., Jaffe E. S., Rosenberg S. A. In vivo administration of purified Jurkat-derived interleukin 2 in mice. Cancer Res. 1984 Apr;44(4):1380–1386. [PubMed] [Google Scholar]
  7. Donohue J. H., Rosenberg S. A. The fate of interleukin-2 after in vivo administration. J Immunol. 1983 May;130(5):2203–2208. [PubMed] [Google Scholar]
  8. Doyle M. V., Lee M. T., Fong S. Comparison of the biological activities of human recombinant interleukin-2(125) and native interleukin-2. J Biol Response Mod. 1985 Feb;4(1):96–109. [PubMed] [Google Scholar]
  9. Ettinghausen S. E., Lipford E. H., 3rd, Mulé J. J., Rosenberg S. A. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. J Immunol. 1985 Aug;135(2):1488–1497. [PubMed] [Google Scholar]
  10. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  11. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  12. Maack T., Johnson V., Kau S. T., Figueiredo J., Sigulem D. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 1979 Sep;16(3):251–270. doi: 10.1038/ki.1979.128. [DOI] [PubMed] [Google Scholar]
  13. Matory Y. L., Chang A. E., Lipford E. H., 3rd, Braziel R., Hyatt C. L., McDonald H. D., Rosenberg S. A. Toxicity of recombinant human interleukin-2 in rats following intravenous infusion. J Biol Response Mod. 1985 Aug;4(4):377–390. [PubMed] [Google Scholar]
  14. Miron T., Wilchek M. A spectrophotometric assay for soluble and immobilized N-hydroxysuccinimide esters. Anal Biochem. 1982 Nov 1;126(2):433–435. doi: 10.1016/0003-2697(82)90540-1. [DOI] [PubMed] [Google Scholar]
  15. Mulé J. J., Shu S., Rosenberg S. A. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol. 1985 Jul;135(1):646–652. [PubMed] [Google Scholar]
  16. Mühlradt P. F., Opitz H. G. Clearance of interleukin 2 from the blood of normal and T cell-depleted mice. Eur J Immunol. 1982 Nov;12(11):983–985. doi: 10.1002/eji.1830121117. [DOI] [PubMed] [Google Scholar]
  17. Righetti P. G., Gianazza E. New developments in isoelectric focusing. J Chromatogr. 1980 Nov 7;184(4):415–456. doi: 10.1016/s0021-9673(00)93873-1. [DOI] [PubMed] [Google Scholar]
  18. Robb R. J. Human interleukin 2. Methods Enzymol. 1985;116:493–525. doi: 10.1016/s0076-6879(85)16040-4. [DOI] [PubMed] [Google Scholar]
  19. Rosenberg S. A., Grimm E. A., McGrogan M., Doyle M., Kawasaki E., Koths K., Mark D. F. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984 Mar 30;223(4643):1412–1414. doi: 10.1126/science.6367046. [DOI] [PubMed] [Google Scholar]
  20. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  21. Rosenberg S. A., Mulé J. J., Spiess P. J., Reichert C. M., Schwarz S. L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985 May 1;161(5):1169–1188. doi: 10.1084/jem.161.5.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sokoloff R. L., Frigon R. P. Rapid spectrophotometric assay of dodecyl sulfate using acridine orange. Anal Biochem. 1981 Nov 15;118(1):138–141. doi: 10.1016/0003-2697(81)90169-x. [DOI] [PubMed] [Google Scholar]
  23. Ueno Y., Miyawaki T., Seki H., Hara K., Sato T., Taniguchi N., Takahashi H., Kondo N. Impaired natural killer cell activity in Bloom's syndrome could be restored by human recombinant IL-2 in vitro. Clin Immunol Immunopathol. 1985 May;35(2):226–233. doi: 10.1016/0090-1229(85)90068-6. [DOI] [PubMed] [Google Scholar]
  24. Vinogradov S. N., Kapp O. H. Removal of sodium dodecyl sulfate from proteins by ion-retardation chromatography. Methods Enzymol. 1983;91:259–263. doi: 10.1016/s0076-6879(83)91023-6. [DOI] [PubMed] [Google Scholar]
  25. Wang A., Lu S. D., Mark D. F. Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. Science. 1984 Jun 29;224(4656):1431–1433. doi: 10.1126/science.6427925. [DOI] [PubMed] [Google Scholar]
  26. Watson J. Continuous proliferation of murine antigen-specific helper T lymphocytes in culture. J Exp Med. 1979 Dec 1;150(6):1510–1519. doi: 10.1084/jem.150.6.1510. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES